ERBB2 and breast carcinoma: It’s also worth noting that our prognostic model was applicable to all breast cancer patients with different clinical stages or molecular subtypes (HR-positive/luminal, HER2-positve, or TNBC) while Zhao et al.’s model applied only to early-stage breast cancer patients.